SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
RAPP

Rapport Therapeutics, Inc. (RAPP)

NASDAQ: RAPP · USD
Healthcare · Biotechnology
$23.16-$0.43 (-1.82%)
 
Market cap
$1.37B
Insider Score
Analyst consensus
Market Cap$1.37B-13.7%
Revenue (ttm)$20.00M
Net Income-$150.47M
EPS-$3.17
Shares Out59.28M
PE Ration/a
Forward PE-5.84
Dividendn/a
Ex-Dividend Daten/a
Volume437,720
Open$23.23
Previous Close$23.59
Day's Range$23.00 - $23.83
52-Week Range$22.06 - $52.93
Beta1.40
AnalystsStrong Buy
Price Target$64.21(+177.26%)
Earnings DateNov 4, 2026

About RAPP

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.

Address
99 High Street, Boston, MA, 02110, United States
Market Cap
1.37 billion
Employees
84
Industrial Classification
Biotechnology

Rapport Therapeutics, Inc. Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
50th Percentile Overall Score
RAPP InsiderScore:68 / 99

Rapport Therapeutics, Inc. scored higher than 50% of companies evaluated by InsiderBuying, and ranked 42nd out of 107 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Rapport Therapeutics, Inc. bought $22.02 million of stock across 11 purchases in the last 90 days, the largest of them $20.00 million.

Stake Increase

The average purchase added about 46% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

3 of these purchases were made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$4.47M
Bought
$22.02M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
6 Buy0 Hold0 SellAvg target $74.00 (+214.1%)

6 firms rating RAPP in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-1.82%
5 Days
-11.43%
1 Month
-12.70%
6 Months
-38.60%
1 Year
-13.74%

$RAPP stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in RAPP holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by RAPP's directors and management

Net Shares Purchased by Insiders−2M−1M02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

RAPP Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New RAPP patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to RAPP from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from RAPP’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
66.66
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
45

News check: Only one headline directly addresses RAPP, suggesting valuation concerns despite recent decline; limited concrete news to establish clear bullish or bearish sentiment.

Recent Insider Activity

Buys
11
Sells
14
Buy Value
$22.02M
Distinct Buyers
7

Insider Score Trend Over Time

+67.8 since Sep 4
0255075100Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 24.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Oct 25 — Insider Score 68.3Oct 26 — Insider Score 68.3Oct 27 — Insider Score 68.3Oct 28 — Insider Score 68.3Oct 29 — Insider Score 68.3Oct 30 — Insider Score 68.3Oct 31 — Insider Score 68.7Nov 1 — Insider Score 68.7Nov 2 — Insider Score 68.7Nov 3 — Insider Score 68.7Nov 4 — Insider Score 68.7Nov 5 — Insider Score 68.7Nov 6 — Insider Score 68.7Nov 7 — Insider Score 68.7Nov 8 — Insider Score 68.7Nov 9 — Insider Score 68.7Nov 10 — Insider Score 68.6Nov 11 — Insider Score 68.5Nov 12 — Insider Score 68.5Nov 13 — Insider Score 68.5Nov 14 — Insider Score 68.4Nov 15 — Insider Score 68.4Nov 16 — Insider Score 68.4Nov 17 — Insider Score 68.3Nov 18 — Insider Score 68.2Nov 19 — Insider Score 68.0Nov 20 — Insider Score 67.9Nov 21 — Insider Score 67.8Nov 22 — Insider Score 67.8Sep 4Oct 3Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

IBRNiShares Neuroscience and Healthcare ETF1.11%
XPHState Street SPDR S&P Pharmaceuticals ETF1.09%
SBIOALPS Medical Breakthroughs ETF0.81%
BBCVirtus Biotech Clinical Trials ETF0.52%
DWASInvesco Dorsey Wright SmallCap Momentum ETF0.40%
IHEiShares U.S. Pharmaceuticals ETF0.24%
MNTLTema Neuroscience And Mental Health ETF0.21%
IWCiShares Micro-Cap ETF0.20%
PILLDirexion Daily Pharmaceutical & Medical Bull 3X ETF0.16%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF0.16%
FSEGFidelity Enhanced Small Cap Growth ETF0.15%
FSCCFederated Hermes MDT Small Cap Core ETF0.12%

Weight is the stock’s share of each fund’s holdings.